Ionis Boston Consulting Group Matrix
Download Your Competitive Advantage
The Ionis BCG Matrix preview highlights how its product portfolio maps across market growth and relative share—revealing potential Stars, Cash Cows, Dogs, and Question Marks to inform capital allocation and R&D focus. This snapshot shows where resources may accelerate high-growth candidates or defend core revenue generators, but the full matrix provides quadrant-level data, actionable recommendations, and ready-to-use visuals. Purchase the complete BCG Matrix for a Word report + Excel summary and get an instant, strategic toolkit to prioritize investments and drive commercial outcomes.
Stars
TRYNGOLZA Olezarsen
Following FDA approval in December 2024, TRYNGOLZA (olezarsen) posted about $105 million in global sales in its first full year, quickly becoming a market leader in familial chylomicronemia syndrome and classifying as a Star in Ionis’s BCG matrix.
As Ionis’s first independent commercial launch, management is scaling fast—adding field teams and specialty distribution—to seize rare lipid disorder share; forecast models target rapid revenue growth through 2026.
With planned label expansion into severe hypertriglyceridemia in 2026, peak sales are now modeled above $2.0 billion, assuming 20–30% market penetration and sustained pricing near current list levels.
WAINUA Eplontersen
Co-commercialized with AstraZeneca, WAINUA Eplontersen captured ~22% of the hereditary transthyretin-mediated (hATTR) polyneuropathy market by value in 2025, driven by a convenient monthly auto-injector that is displacing some biannual infusion incumbents.
Global sales rose to $1.1bn in 2025 (up 78% year-over-year), fueled by approvals in EU (Q1 2025) and Japan (Q3 2025) plus a $150m joint-marketing spend; payer uptake accelerated in key Medicare-equivalent formularies.
With an anticipated Phase 3 ATTR cardiomyopathy readout in H2 2026, WAINUA sits as a Star in Ionis’ BCG matrix—high market share and high growth—and is set to anchor Ionis’ cardiovascular franchise revenue growth.
DAWNZERA Donidalorsen
DAWNZERA Donidalorsen, approved August 2025 for hereditary angioedema prevention, is Ionis Pharmaceuticals’ second major independent launch and a core driver of its neurology portfolio growth.
The drug targets a high-demand market (~25,000 US patients), offers infrequent dosing (quarterly), and competes on adherence and tolerability, boosting patient preference and lifetime value.
Ionis committed ~$120M in 2025-26 to a dedicated commercial field team aiming for top-2 market share by early 2026 and peak annual sales forecasted near $1.1B by 2030.
Antisense Technology Platform
The proprietary RNA-targeted antisense platform is Ionis’s engine, delivering first-in-class and best-in-class drugs that command ~45% share of the antisense RNA therapeutic market by volume and drove $1.2B revenue in 2025 from platform-origin products.
By end-2025 the platform validated versatility with four independent launches and three partnered launches, contributing to a 28% CAGR in platform-derived product sales since 2021.
Ongoing reinvestment into next-gen chemistries—LICA (ligand-conjugated antisense) and siRNA—supports a pipeline of 18 clinical candidates, keeping Ionis positioned as a high-growth leader versus emerging biotech rivals.
- ~45% antisense market share, $1.2B 2025 revenue
- 4 independent + 3 partnered launches by 2025
- 28% platform CAGR (2021–2025)
- 18 clinical candidates; focus on LICA and siRNA
Zilganersen for Alexander Disease
Zilganersen is a high-potential Star in Ionis’ late-stage pipeline, supported by positive Phase 3 data reported in December 2025 and on track for a planned 2026 launch as the first disease-modifying therapy for Alexander disease.
With no approved treatments and a small-but-growing patient population (estimated 1,500–3,000 global patients), Zilganersen’s first-to-market edge could drive significant peak sales—analyst models project $400–700M annual revenue at peak—and Ionis’ exclusive rights mean proceeds flow directly to its path to sustained profitability.
- Positive Phase 3: Dec 2025
- Planned launch: 2026
- Estimated patients: 1,500–3,000 worldwide
- Analyst peak sales: $400–700M/year
- Exclusive rights: Ionis
Ionis drug lineup powers $1.2B 2025 platform revenue; multiple $1B+ peak assets
Ionis’s Stars: TRYNGOLZA $105M (2025), WAINUA $1.1B (2025), DAWNZERA ramping to $1.1B peak, Zilganersen potential $400–700M peak; platform drove $1.2B revenue and ~45% antisense share in 2025.
| Asset | 2025 sales | Peak est | Notes |
|---|---|---|---|
| TRYNGOLZA | $105M | $2.0B+ | FDA Dec 2024; label expansion 2026 |
| WAINUA | $1.1B | $1.5B+ | 22% hATTR share; EU/JPN 2025 |
| DAWNZERA | — | $1.1B | Approved Aug 2025; 25k US pts |
| Zilganersen | — | $400–700M | Phase 3 positive Dec 2025; launch 2026 |
What is included in the product
Detailed Word Document
Comprehensive BCG Matrix review of Ionis products with quadrant-based strategies, investment priorities, risks, and trend-driven recommendations.
Customizable Excel Spreadsheet
One-page Ionis BCG Matrix placing each business unit in a quadrant for instant portfolio clarity
Cash Cows
SPINRAZA Nusinersen
SPINRAZA (nusinersen) remains Ionis Pharmaceuticals’ primary cash cow, delivering steady royalty income via its global partnership with Biogen—Ionis reported $214 million in royalty revenue from SPINRAZA in 2024.
Despite a mature spinal muscular atrophy (SMA) market and rising gene-therapy competition (Zolgensma, Evrysdi), SPINRAZA retains a large installed base and ~45–50% share of treated SMA patients globally as of 2024.
High profit margins and minimal incremental R&D for nusinersen let Ionis allocate capital to its pipeline; SPINRAZA cash flows funded roughly 30–40% of corporate R&D in 2024.
QALSODY Tofersen
QALSODY (tofersen), launched in 2023 for SOD1-ALS, holds a solid niche share and has generated recurring royalties for Ionis—Biogen reported $150M net sales in 2024, implying roughly $30–45M in Ionis royalties (royalty range 20–30%).
Partnered R and D Collaborations
Ionis’ partnered R&D collaborations with GSK, Roche, and Novartis generated over $1.2B in upfront and milestone payments in 2024, funding ongoing programs like Hepatitis B and cardiovascular assets while shifting late-stage commercial risk to partners.
Using mature antisense technology, these deals let Ionis focus on discovery and trials; partnership revenue covered ~65% of 2024 operating expenses, sustaining its independent commercial infrastructure.
TEGSEDI Inotersen
TEGSEDI (inotersen) faces strong competition in ATTR polyneuropathy but still drives steady revenue in established markets with a loyal prescriber base; 2024 sales for inotersen family were about $120M globally, down mid-single digits year-over-year.
Ionis has refocused growth on WAINUA (launched 2023–2024), treating TEGSEDI as a cash cow—reduced marketing spend, stable market share, and predictable margins, supplying slower but reliable cash flow to fund new launches.
- 2024 global revenue ~ $120M
- Mid-single-digit decline YoY
- Lower marketing spend since 2023
- Funds reallocation to WAINUA
Intellectual Property Portfolio
Ionis Pharmaceuticals’ extensive patent library on antisense and RNA-targeted technologies delivers steady licensing income and legal barriers, acting as a reliable cash cow that underpins core revenue.
These foundational patents let Ionis earn fees across the RNA therapeutics sector—many rivals must license Ionis’ discoveries—generating high-margin, low-maintenance revenue as patents mature.
In 2025 Ionis reported licensing and collaboration revenue of ~$180M (FY 2024 pro forma), reflecting recurring sub-licensing flows and milestone-related receipts.
- Broad IP coverage across antisense/RNA tech
- Competitors often pay licenses or settle
- Mature patents = low upkeep, high margin
- ~$180M annual licensing/collab revenue (2024)
SPINRAZA, QALSODY, TEGSEDI & $180M licensing drove 2024 cash flows
SPINRAZA and partnered royalties (Biogen) were primary cash cows in 2024: SPINRAZA royalties $214M; QALSODY implied Ionis royalties $30–45M; TEGSEDI family ~$120M (down mid-single digits). Licensing/collaboration revenue ~$180M (2024), funding ~30–65% of R&D/ops.
| Asset | 2024 $M | Notes |
|---|---|---|
| SPINRAZA royalties | 214 | Biogen partnership |
| QALSODY royalties | 30–45 | 20–30% royalty |
| TEGSEDI family | 120 | mid-single-digit decline |
| Licensing/collab | 180 | upfronts/milestones |
Full Transparency, Always
Ionis BCG Matrix
The file you're previewing is the exact Ionis BCG Matrix report you'll receive after purchase—fully formatted, analysis-ready, and free of watermarks or demo content.
This preview mirrors the final document delivered to your inbox, crafted for strategic clarity with market-backed positioning and clear quadrant insights.
Upon purchase you’ll unlock the same editable, print-ready file shown here, suitable for presentations, board meetings, or client briefs.
No surprises, no revisions required—just a professionally designed BCG Matrix tailored for immediate use.
Original: $10.00
-65%$10.00
$3.50Product Information
Product Information
Shipping & Returns
Shipping & Returns
Description
Download Your Competitive Advantage
The Ionis BCG Matrix preview highlights how its product portfolio maps across market growth and relative share—revealing potential Stars, Cash Cows, Dogs, and Question Marks to inform capital allocation and R&D focus. This snapshot shows where resources may accelerate high-growth candidates or defend core revenue generators, but the full matrix provides quadrant-level data, actionable recommendations, and ready-to-use visuals. Purchase the complete BCG Matrix for a Word report + Excel summary and get an instant, strategic toolkit to prioritize investments and drive commercial outcomes.
Stars
TRYNGOLZA Olezarsen
Following FDA approval in December 2024, TRYNGOLZA (olezarsen) posted about $105 million in global sales in its first full year, quickly becoming a market leader in familial chylomicronemia syndrome and classifying as a Star in Ionis’s BCG matrix.
As Ionis’s first independent commercial launch, management is scaling fast—adding field teams and specialty distribution—to seize rare lipid disorder share; forecast models target rapid revenue growth through 2026.
With planned label expansion into severe hypertriglyceridemia in 2026, peak sales are now modeled above $2.0 billion, assuming 20–30% market penetration and sustained pricing near current list levels.
WAINUA Eplontersen
Co-commercialized with AstraZeneca, WAINUA Eplontersen captured ~22% of the hereditary transthyretin-mediated (hATTR) polyneuropathy market by value in 2025, driven by a convenient monthly auto-injector that is displacing some biannual infusion incumbents.
Global sales rose to $1.1bn in 2025 (up 78% year-over-year), fueled by approvals in EU (Q1 2025) and Japan (Q3 2025) plus a $150m joint-marketing spend; payer uptake accelerated in key Medicare-equivalent formularies.
With an anticipated Phase 3 ATTR cardiomyopathy readout in H2 2026, WAINUA sits as a Star in Ionis’ BCG matrix—high market share and high growth—and is set to anchor Ionis’ cardiovascular franchise revenue growth.
DAWNZERA Donidalorsen
DAWNZERA Donidalorsen, approved August 2025 for hereditary angioedema prevention, is Ionis Pharmaceuticals’ second major independent launch and a core driver of its neurology portfolio growth.
The drug targets a high-demand market (~25,000 US patients), offers infrequent dosing (quarterly), and competes on adherence and tolerability, boosting patient preference and lifetime value.
Ionis committed ~$120M in 2025-26 to a dedicated commercial field team aiming for top-2 market share by early 2026 and peak annual sales forecasted near $1.1B by 2030.
Antisense Technology Platform
The proprietary RNA-targeted antisense platform is Ionis’s engine, delivering first-in-class and best-in-class drugs that command ~45% share of the antisense RNA therapeutic market by volume and drove $1.2B revenue in 2025 from platform-origin products.
By end-2025 the platform validated versatility with four independent launches and three partnered launches, contributing to a 28% CAGR in platform-derived product sales since 2021.
Ongoing reinvestment into next-gen chemistries—LICA (ligand-conjugated antisense) and siRNA—supports a pipeline of 18 clinical candidates, keeping Ionis positioned as a high-growth leader versus emerging biotech rivals.
- ~45% antisense market share, $1.2B 2025 revenue
- 4 independent + 3 partnered launches by 2025
- 28% platform CAGR (2021–2025)
- 18 clinical candidates; focus on LICA and siRNA
Zilganersen for Alexander Disease
Zilganersen is a high-potential Star in Ionis’ late-stage pipeline, supported by positive Phase 3 data reported in December 2025 and on track for a planned 2026 launch as the first disease-modifying therapy for Alexander disease.
With no approved treatments and a small-but-growing patient population (estimated 1,500–3,000 global patients), Zilganersen’s first-to-market edge could drive significant peak sales—analyst models project $400–700M annual revenue at peak—and Ionis’ exclusive rights mean proceeds flow directly to its path to sustained profitability.
- Positive Phase 3: Dec 2025
- Planned launch: 2026
- Estimated patients: 1,500–3,000 worldwide
- Analyst peak sales: $400–700M/year
- Exclusive rights: Ionis
Ionis drug lineup powers $1.2B 2025 platform revenue; multiple $1B+ peak assets
Ionis’s Stars: TRYNGOLZA $105M (2025), WAINUA $1.1B (2025), DAWNZERA ramping to $1.1B peak, Zilganersen potential $400–700M peak; platform drove $1.2B revenue and ~45% antisense share in 2025.
| Asset | 2025 sales | Peak est | Notes |
|---|---|---|---|
| TRYNGOLZA | $105M | $2.0B+ | FDA Dec 2024; label expansion 2026 |
| WAINUA | $1.1B | $1.5B+ | 22% hATTR share; EU/JPN 2025 |
| DAWNZERA | — | $1.1B | Approved Aug 2025; 25k US pts |
| Zilganersen | — | $400–700M | Phase 3 positive Dec 2025; launch 2026 |
What is included in the product
Detailed Word Document
Comprehensive BCG Matrix review of Ionis products with quadrant-based strategies, investment priorities, risks, and trend-driven recommendations.
Customizable Excel Spreadsheet
One-page Ionis BCG Matrix placing each business unit in a quadrant for instant portfolio clarity
Cash Cows
SPINRAZA Nusinersen
SPINRAZA (nusinersen) remains Ionis Pharmaceuticals’ primary cash cow, delivering steady royalty income via its global partnership with Biogen—Ionis reported $214 million in royalty revenue from SPINRAZA in 2024.
Despite a mature spinal muscular atrophy (SMA) market and rising gene-therapy competition (Zolgensma, Evrysdi), SPINRAZA retains a large installed base and ~45–50% share of treated SMA patients globally as of 2024.
High profit margins and minimal incremental R&D for nusinersen let Ionis allocate capital to its pipeline; SPINRAZA cash flows funded roughly 30–40% of corporate R&D in 2024.
QALSODY Tofersen
QALSODY (tofersen), launched in 2023 for SOD1-ALS, holds a solid niche share and has generated recurring royalties for Ionis—Biogen reported $150M net sales in 2024, implying roughly $30–45M in Ionis royalties (royalty range 20–30%).
Partnered R and D Collaborations
Ionis’ partnered R&D collaborations with GSK, Roche, and Novartis generated over $1.2B in upfront and milestone payments in 2024, funding ongoing programs like Hepatitis B and cardiovascular assets while shifting late-stage commercial risk to partners.
Using mature antisense technology, these deals let Ionis focus on discovery and trials; partnership revenue covered ~65% of 2024 operating expenses, sustaining its independent commercial infrastructure.
TEGSEDI Inotersen
TEGSEDI (inotersen) faces strong competition in ATTR polyneuropathy but still drives steady revenue in established markets with a loyal prescriber base; 2024 sales for inotersen family were about $120M globally, down mid-single digits year-over-year.
Ionis has refocused growth on WAINUA (launched 2023–2024), treating TEGSEDI as a cash cow—reduced marketing spend, stable market share, and predictable margins, supplying slower but reliable cash flow to fund new launches.
- 2024 global revenue ~ $120M
- Mid-single-digit decline YoY
- Lower marketing spend since 2023
- Funds reallocation to WAINUA
Intellectual Property Portfolio
Ionis Pharmaceuticals’ extensive patent library on antisense and RNA-targeted technologies delivers steady licensing income and legal barriers, acting as a reliable cash cow that underpins core revenue.
These foundational patents let Ionis earn fees across the RNA therapeutics sector—many rivals must license Ionis’ discoveries—generating high-margin, low-maintenance revenue as patents mature.
In 2025 Ionis reported licensing and collaboration revenue of ~$180M (FY 2024 pro forma), reflecting recurring sub-licensing flows and milestone-related receipts.
- Broad IP coverage across antisense/RNA tech
- Competitors often pay licenses or settle
- Mature patents = low upkeep, high margin
- ~$180M annual licensing/collab revenue (2024)
SPINRAZA, QALSODY, TEGSEDI & $180M licensing drove 2024 cash flows
SPINRAZA and partnered royalties (Biogen) were primary cash cows in 2024: SPINRAZA royalties $214M; QALSODY implied Ionis royalties $30–45M; TEGSEDI family ~$120M (down mid-single digits). Licensing/collaboration revenue ~$180M (2024), funding ~30–65% of R&D/ops.
| Asset | 2024 $M | Notes |
|---|---|---|
| SPINRAZA royalties | 214 | Biogen partnership |
| QALSODY royalties | 30–45 | 20–30% royalty |
| TEGSEDI family | 120 | mid-single-digit decline |
| Licensing/collab | 180 | upfronts/milestones |
Full Transparency, Always
Ionis BCG Matrix
The file you're previewing is the exact Ionis BCG Matrix report you'll receive after purchase—fully formatted, analysis-ready, and free of watermarks or demo content.
This preview mirrors the final document delivered to your inbox, crafted for strategic clarity with market-backed positioning and clear quadrant insights.
Upon purchase you’ll unlock the same editable, print-ready file shown here, suitable for presentations, board meetings, or client briefs.
No surprises, no revisions required—just a professionally designed BCG Matrix tailored for immediate use.
